Cellectis鈥� Annual Shareholders General Meeting听to be Held on June 26, 2025
Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company focused on gene-editing and cell and gene therapies, has announced its upcoming annual shareholders general meeting. The meeting is scheduled for June 26, 2025, at 2:30 p.m. CET and will be held at the Biopark auditorium in Paris, France. Shareholders can access detailed information about the meeting agenda and participation modalities through the company's website.
Cellectis (NASDAQ: CLLS), un'azienda biotecnologica in fase clinica specializzata in editing genetico e terapie cellulari e geniche, ha annunciato la prossima assemblea annuale degli azionisti. L'incontro 猫 previsto per il 26 giugno 2025, alle 14:30 CET e si terr脿 nell'auditorium Biopark a Parigi, Francia. Gli azionisti possono trovare informazioni dettagliate sull'ordine del giorno e sulle modalit脿 di partecipazione sul sito web dell'azienda.
Cellectis (NASDAQ: CLLS), una empresa biotecnol贸gica en fase cl铆nica centrada en la edici贸n gen茅tica y terapias celulares y g茅nicas, ha anunciado su pr贸xima junta anual de accionistas. La reuni贸n est谩 programada para el 26 de junio de 2025 a las 14:30 CET y se llevar谩 a cabo en el auditorio Biopark en Par铆s, Francia. Los accionistas pueden acceder a informaci贸n detallada sobre la agenda y las modalidades de participaci贸n a trav茅s del sitio web de la empresa.
Cellectis (NASDAQ: CLLS)電� 鞙犾爠鞛� 韼胳 氚� 靹疙彫 氚� 鞙犾爠鞛� 旃橂鞐� 欷戩爯鞚� 霊� 鞛勳儊 雼硠鞚� 靸濍獏瓿淀暀 須岇偓搿�, 瓿� 臧滌禍霅� 鞐半 欤检＜齑濏殞毳� 氚滍憸頄堨姷雼堧嫟. 齑濏殞電� 2025雲� 6鞗� 26鞚� 鞓ろ泟 2鞁� 30攵� CET鞐� 頂勲瀾鞀� 韺岆Μ鞚� Biopark 臧曤嫻鞐愳劀 鞐措Υ 鞓堨爼鞛呺媹雼�. 欤检＜霌れ潃 須岇偓 鞗轨偓鞚错姼毳� 韱淀暣 須岇潣 鞎堦贝瓿� 彀胳棳 氚╇矔鞐� 雽�頃� 鞛愳劯頃� 鞝曤炒毳� 頇曥澑頃� 靾� 鞛堨姷雼堧嫟.
Cellectis (NASDAQ : CLLS), une soci茅t茅 de biotechnologie en phase clinique sp茅cialis茅e dans l'茅dition g茅n茅tique ainsi que les th茅rapies cellulaires et g茅niques, a annonc茅 sa prochaine assembl茅e g茅n茅rale annuelle des actionnaires. Cette r茅union est pr茅vue pour le 26 juin 2025 脿 14h30 CET et se tiendra dans l'auditorium du Biopark 脿 Paris, France. Les actionnaires peuvent consulter des informations d茅taill茅es sur l'ordre du jour et les modalit茅s de participation sur le site web de la soci茅t茅.
Cellectis (NASDAQ: CLLS), ein biotechnologisches Unternehmen in der klinischen Entwicklungsphase mit Fokus auf Gen-Editing sowie Zell- und Gentherapien, hat seine bevorstehende j盲hrliche Hauptversammlung angek眉ndigt. Die Versammlung ist f眉r den 26. Juni 2025 um 14:30 Uhr MEZ geplant und findet im Biopark-Auditorium in Paris, Frankreich, statt. Aktion盲re k枚nnen ausf眉hrliche Informationen zur Tagesordnung und den Teilnahmebedingungen auf der Unternehmenswebsite einsehen.
- None.
- None.
NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Cellectis (the 鈥淐ompany鈥�) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 26, 2025 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.
The notice convening the annual general meeting stating the detailed agenda and modalities of participation in the meeting and the report of the board of directors to the shareholders meeting are available on the Cellectis website:
About Cellectis鈥赌赌赌�
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish.
Cellectis鈥� headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit and follow Cellectis on and .
For further information on Cellectis, please contact:听听听听听
Media contacts:听听听听听
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, 听听听听听
Patricia Sosa Navarro, Chief of Staff to the CEO,听+33 (0)7 76 77 46 93听听
Investor Relations contact:听听听听听听听
Arthur Stril, Chief Financial Officer & Chief Business Officer,
听
Attachment
FAQ
When and where is Cellectis (CLLS) holding its 2025 annual shareholders meeting?
How can shareholders access information about Cellectis' 2025 annual meeting?
What is Cellectis (CLLS) main business focus?
On which stock exchanges is Cellectis traded?
